Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi. K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia Borges, Vandana Abramson, Carey Anders, Philippe L. Bedard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit S. Shachar, Volkmar Müller, Sofia Braga, Francois P. Duhoux, Richard Greil, David CameronLisa A. Carey, Giuseppe Curigliano, Karen Gelmon, Gabriel Hortobagyi, Ian Krop, Sibylle Loibl, Mark Pegram, Dennis Slamon, M. Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences